Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls

Molecular Therapy

Volumn 22, Issue 11, 2014, Pages 1960-1970

  Gremmels, Hendrik ^a   Teraa, Martin ^a   Quax, Paul H A ^b   Den Ouden, Krista ^a   Fledderus, Joost O ^a   Verhaar, Marianne C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR;

ADIPOGENESIS; ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL AGING; CELL DIFFERENTIATION; CELL MIGRATION; CELL TRANSPLANTATION; CHONDROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; FEMALE; GENE EXPRESSION; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STROMA CELL; MOUSE; MURINE; NONHUMAN; REPERFUSION;

EID: 84908192402     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.161     Document Type: Article

References (50)

1. Norgren, L, Hiatt, WR, Dormandy, JA, Nehler, MR, Harris, KA and Fowkes, FG; TASC II Working Group (2007). Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 Suppl S: 55-67.
2. Sprengers, RW, Teraa, M, Moll, FL, de Wit, GA, van der Graaf, Y and Verhaar, MC; JUVENTAS Study Group; SMART Study Group (2010). Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg 52: 843-9, 849.e1.
3. Higashi, Y, Kimura, M, Hara, K, Noma, K, Jitsuiki, D, Nakagawa, K et al. (2004). Autologous bone-marrow mononuclear cell implantation improves endotheliumdependent vasodilation in patients with limb ischemia. Circulation 109: 1215-1218.
4. Teraa, M, Sprengers, RW, van der Graaf, Y, Peters, CE, Moll, FL and Verhaar, MC (2013). Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 258: 922-929.
5. Heeschen, C, Lehmann, R, Honold, J, Assmus, B, Aicher, A, Walter, DH et al. (2004). Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615-1622.
6. Li, TS, Kubo, M, Ueda, K, Murakami, M, Ohshima, M, Kobayashi, T et al. (2009). Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients. Circulation 120(11 Suppl): S255-S261.
7. Iwase, T, Nagaya, N, Fujii, T, Itoh, T, Murakami, S, Matsumoto, T et al. (2005). Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 66: 543-551.
8. Lasala, GP, Silva, JA, Kusnick, BA and Minguell, JJ (2011). Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc Revasc Med 12: 29-34.
9. Crisan, M, Yap, S, Casteilla, L, Chen, CW, Corselli, M, Park, TS et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313.
10. Pittenger, MF, Mackay, AM, Beck, SC, Jaiswal, RK, Douglas, R, Mosca, JD et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
11. Murphy, MB, Moncivais, K and Caplan, AI (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45: e54.
12. Gremmels, H, Fledderus, JO, Teraa, M and Verhaar, MC (2013). Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective. Stem Cell Res Ther 4: 140.
13. Meisel, R, Zibert, A, Laryea, M, Göbel, U, Däubener, W and Dilloo, D (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621.
14. Le Blanc, K, Tammik, C, Rosendahl, K, Zetterberg, E and Ringdén, O (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890-896.
15. Huang, XP, Sun, Z, Miyagi, Y, McDonald Kinkaid, H, Zhang, L, Weisel, RD et al. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122: 2419-2429.
16. Nauta, AJ, Westerhuis, G, Kruisselbrink, AB, Lurvink, EG, Willemze, R and Fibbe, WE (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
17. Hare, JM, Fishman, JE, Gerstenblith, G, DiFede Velazquez, DL, Zambrano, JP, Suncion, VY et al. (2012). Comparison of allogeneic vs autologous bone marrow- derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 308: 2369-2379.
18. Hare, JM, Traverse, JH, Henry, TD, Dib, N, Strumpf, RK, Schulman, SP et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54: 2277-2286.
19. Sun, LY, Zhang, HY, Feng, XB, Hou, YY, Lu, LW and Fan, LM (2007). Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16: 121-128.
20. Guiducci, S, Manetti, M, Romano, E, Mazzanti, B, Ceccarelli, C, Dal Pozzo, S et al. (2011). Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis 70: 2011-2021.
21. Fan, M, Chen, W, Liu, W, Du, GQ, Jiang, SL, Tian, WC et al. (2010). The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res 13: 429-438.
22. Roemeling-van Rhijn, M, Reinders, ME, de Klein, A, Douben, H, Korevaar, SS, Mensah, FK et al. (2012). Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 82: 748-758.
23. Reinders, ME, Roemeling-van Rhijn, M, Khairoun, M, Lievers, E, de Vries, DK, Schaapherder, AF et al. (2013). Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy 15: 663-672.
24. Friis, T, Haack-Sørensen, M, Hansen, SK, Hansen, L, Bindslev, L and Kastrup, J (2011). Comparison of mesenchymal stromal cells from young healthy donors and patients with severe chronic coronary artery disease. Scand J Clin Lab Invest 71: 193-202.
25. Neef, K, Choi, YH, Weichel, A, Rahmanian, PB, Liakopoulos, OJ, Stamm, C et al. (2012). The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy 14: 670-678.
26. Boeuf, S, Kunz, P, Hennig, T, Lehner, B, Hogendoorn, P, Bovée, J et al. (2008). A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. J Pathol 216: 158-166.
27. Alves, H, van Ginkel, J, Groen, N, Hulsman, M, Mentink, A, Reinders, M et al. (2012). A mesenchymal stromal cell gene signature for donor age. PLoS ONE 7: e42908.
28. Schwarz, TM, Leicht, SF, Radic, T, Rodriguez-Araboalaza, I, Hermann, PC, Berger, F et al. (2012). Vascular incorporation of endothelial colony-forming cells is essential for functional recovery of murine ischemic tissue following cell therapy. Arterioscler Thromb Vasc Biol 32: e13-e21.
29. Teraa, M, Sprengers, RW, Westerweel, PE, Gremmels, H, Goumans, MJ, Teerlink, T et al.; JUVENTAS study group. (2013). Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS ONE 8: e55592.
30. Sorrentino, SA, Bahlmann, FH, Besler, C, Müller, M, Schulz, S, Kirchhoff, N et al. (2007). Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116: 163-173.
31. Yan, J, Tie, G, Wang, S, Messina, KE, DiDato, S, Guo, S et al. (2012). Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice. J Am Heart Assoc 1: e002238.
32. Larson, BL, Ylöstalo, J and Prockop, DJ (2008). Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 26: 193-201.
33. Boquest, AC, Shahdadfar, A, Frønsdal, K, Sigurjonsson, O, Tunheim, SH, Collas, P et al. (2005). Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell 16: 1131-1141.
34. Urbich, C, Heeschen, C, Aicher, A, Dernbach, E, Zeiher, AM and Dimmeler, S (2003). Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108: 2511-2516.
35. Vasa, M, Fichtlscherer, S, Aicher, A, Adler, K, Urbich, C, Martin, H et al. (2001). Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7.
36. Dawson, K, Wu, CT, Qi, XY and Nattel, S (2012). Congestive heart failure effects on atrial fibroblast phenotype: differences between freshly-isolated and cultured cells. PLoS ONE 7: e52032.
37. Murphy, JM, Dixon, K, Beck, S, Fabian, D, Feldman, A and Barry, F (2002). Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 46: 704-713.
38. Kim, M, Kim, C, Choi, YS, Kim, M, Park, C and Suh, Y (2012). Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: implication to age-associated bone diseases and defects. Mech Ageing Dev 133: 215-225.
39. Stolzing, A, Jones, E, McGonagle, D and Scutt, A (2008). Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 129: 163-173.
40. Ponte, AL, Marais, E, Gallay, N, Langonné, A, Delorme, B, Hérault, O et al. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25: 1737-1745.
41. Ding, W, Knox, TR, Tschumper, RC, Wu, W, Schwager, SM, Boysen, JC et al. (2010). Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 116: 2984-2993.
42. Kinnaird, T, Stabile, E, Burnett, MS, Lee, CW, Barr, S, Fuchs, S et al. (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94: 678-685.
43. Annabi, B, Lee, YT, Turcotte, S, Naud, E, Desrosiers, RR, Champagne, M et al. (2003). Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 21: 337-347.
44. Houtgraaf, JH, de Jong, R, Kazemi, K, de Groot, D, van der Spoel, TI, Arslan, F et al. (2013). Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res 113: 153-166.
45. Coppé, JP, Patil, CK, Rodier, F, Sun, Y, Muñoz, DP, Goldstein, J et al. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
46. Liu, D and Hornsby, PJ (2007). Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 67: 3117-3126.
47. Prockop, DJ (2007). "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther 82: 241-243.
48. Sprengers, RW, Moll, FL, Teraa, M and Verhaar, MC; JUVENTAS Study Group (2010). Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg 51: 1564-1568.
49. Walter, DH, Krankenberg, H, Balzer, JO, Kalka, C, Baumgartner, I, Schlüter, M et al.; PROVASA Investigators. (2011). Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 4: 26-37.
50. Poldervaart, MT, Gremmels, H, van Deventer, K, Fledderus, JO, Oner, FC, Verhaar, MC et al. (2014). Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture. J Control Release 184: 58-66.